Text Size

A Pilot Study of CyberKnife Radiosurgery Delivered to the Partial Breast (CK-PBI)

This study has been completed.
Sponsor:
Information provided by:
Georgetown University
ClinicalTrials.gov Identifier:
NCT00529334
First received: September 12, 2007
Last updated: July 21, 2009
Last verified: September 2007
History of Changes
  Purpose

This pilot study will evaluate the technical feasibility and acute toxicity of Partial Breast Irradiation (PBI) with the CyberKnife in anticipation of a larger multi-institutional Phase II study. It will evaluate quality of life (QOL) issues as they relate to treatment related side effects, cosmetic result, and patient convenience.

Radiosurgery is defined as the stereotactic delivery of ionizing radiation in 5 stages or less to a designated target with sub-millimeter accuracy. Radiosurgery in the context of this protocol will be given to the region of the tumor bed within 7 weeks of lumpectomy and sentinel/axillary node sampling over a period of five to ten days using the CyberKnife (CK). Subjects will receive CK before chemotherapy, if applicable.


Condition Intervention
Breast Cancer
 Radiation: CyberKnife Partial Breast Irradiation

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of CyberKnife Radiosurgery Delivered to the Partial Breast for Women With Stage 0, 1, or IIA (<=3cm) Breast Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Georgetown University:

Primary Outcome Measures:
  • 1. To evaluate the feasibility of CyberKnife body radiosurgery as the sole radiation therapy for this patient population 2. To evaluate the complication rate of CyberKnife body radiosurgery as the sole radiation therapy for this patient population [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • 1. To evaluate the local control rate of CyberKnife body radiosurgery as the sole radiation therapy for this patient population. 2. To evaluate Quality of Life after CyberKnife body radiosurgery PBI. [ Time Frame: 1 - 5 years ]

Estimated Enrollment: 10
Study Start Date: September 2007
Study Completion Date: September 2008
Arms Assigned Interventions
Experimental: 1
CyberKnife Partial Breast Irradiation (PBI)
 Radiation: CyberKnife Partial Breast Irradiation
Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.

  Eligibility

Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • DCIS or infiltrating ductal carcinoma of the breast <= 3cm
  • margins clear by at least 2 mm
  • age >=45 years

Exclusion Criteria:

  • invasive lobular carcinoma
  • multicentric disease
  • nodal metastases
  • breast implants
  • pregnancy
  • connective tissue disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00529334

Locations
United States, District of Columbia
Georgtown University Medical Center
Washington, District of Columbia, United States, 20057
Sponsors and Collaborators
Georgetown University
Investigators
Principal Investigator: Jefferson EC Moulds, MD Georgetown University
  More Information

Additional Information:
Georgetown University Hospital CyberKnife Center  This link exits the ClinicalTrials.gov site
Lombardi Comprehensive Cancer Center Clinical Trials  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00529334     History of Changes
Other Study ID Numbers: GUMC 2007-153
Study First Received: September 12, 2007
Last Updated: July 21, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Georgetown University:
Breast Cancer
Partial breast irradiation
Radiosurgery
 CyberKnife
Radiotherapy
PBI

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on June 18, 2013